Program
ipsoprubart
Its studies are mostly in Lymphohistiocytosis, Hemophagocytic · Lymphoma, led by Electra Therapeutics.
Furthest: phase 3, since Jun 6, 20223 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Electra Therapeutics | 32 open or running | phase 3since Jun 6, 2022 | Jun 6, 2022 | Mar 2028phase 3 · NCT05416307 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 6, 2022First study: phase 3 study in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)First studyNCT05416307 · 156 planned · United States, Austria, Germany and more
- Sep 20, 2022Phase 1 study in Healthy VolunteersNCT05556863 · 91 enrolled · United States, Austria
- Mar 4, 2026Phase 1 study in LymphomaNCT07465835 · 84 planned · United States
Ahead
- Mar 2028Primary completion: phase 3 study in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)NCT05416307
- Jun 2028Primary completion: phase 1 study in LymphomaNCT07465835
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07465835Lymphoma · United States | 1 | Recruiting | Jun 2028 | 84 |
| NCT05556863Healthy Volunteers · United States, Austria | 1 | Completed | Nov 20, 2023 | 91 |
| NCT05416307Secondary Hemophagocytic Lymphohistiocytosis (sHLH) · United States, Austria, Germany and more | 3 | Recruiting | Mar 2028 | 156 |
How it is read
Names in the registry
- “ELA026”, 4 entries
Conditions, from the studies’ own filings
- Lymphohistiocytosis, Hemophagocytic, 1 study
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.